SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling cu
Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term
ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.
Twist Bioscience (TWST) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.94. This compares to loss of $0.91 per share a year ago.

A New Look At Twist Bioscience

04:55pm, Thursday, 02'nd Nov 2023
Today, we take a look synthetic biology company Twist Bioscience Corporation for the first time since spring. The company recently signed collaboration deals with two new drugmakers and saw upward ana
Twist continues to expand its SynBio and NGS businesses, but its Biopharma business has had execution issues. Twist is focused on reducing costs, but it is still probably at least several years from G
DNA is as fundamental to biotechnology as it is to biology itself. From synthetic biology to pharmaceuticals, making and using DNA is usually a necessary first step in bringing a biotech product to ma
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust -

Why Shares of Twist Bioscience Are Up Friday

01:21pm, Friday, 04'th Aug 2023
Twist makes synthetic biology and next-generation sequencing tools. The company reported improved revenue and reduced losses in the quarter.
Twist Bioscience (TWST) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $1.08 per share a year ago.
Cathie Wood's Ark Innovation ETF has been blazing the comeback trail in 2023. Among the fund's various holdings, Twist Biosciences and Exact Sciences stand out as top growth plays right now.

Reconsidering Twist Biosciences

01:28pm, Friday, 19'th May 2023
The stock of Twist Bioscience Corporation has declined more than 60% since our first peek at it in the fall of last year. However, the stock saw its first insider buy in a year last week, and the comp
Biology is the study of life. And synthetic biology is the creation of new life for new purposes.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE